Correction to: Nature Communications https://doi.org/10.1038/s41467-024-48780-6, published online 28 May 2024

In this article in the abstract the word clinical was misspelt as clinicl. Additionally, on page 2 of the article the sentence ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of incident AUD diagnosis’ was incorrect and should have been ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of recurrent AUD diagnosis’. Finally, on page 8 the sentence ‘Fourth the follow-up time for the main analyses was 8 months’ should have read ‘Fourth the follow-up time for the main analyses was 12 months.’ The original article has been corrected.